Sleep and Breathing

, Volume 10, Issue 3, pp 139–146

Association between sleep apnea severity and blood coagulability: treatment effects of nasal continuous positive airway pressure

  • Roland von Känel
  • José S. Loredo
  • Sonia Ancoli-Israel
  • Joel E. Dimsdale
Original Article

Abstract

A prothrombotic state may contribute to the elevated cardiovascular risk in patients with obstructive sleep apnea (OSA). We investigated the relationship between apnea severity and hemostasis factors and effect of continuous positive airway pressure (CPAP) treatment on hemostatic activity. We performed full overnight polysomnography in 44 OSA patients (mean age 47±10 years), yielding apnea–hypopnea index (AHI) and mean nighttime oxyhemoglobin saturation (SpO2) as indices of apnea severity. For treatment, subjects were double-blind randomized to 2 weeks of either therapeutic CPAP (n=18), 3 l/min supplemental nocturnal oxygen (n=16) or placebo–CPAP (<1 cm H2O) (n=10). Levels of von Willebrand factor antigen (VWF:Ag), soluble tissue factor (sTF), D-dimer, and plasminogen activator inhibitor (PAI)-1 antigen were measured in plasma pre- and posttreatment. Before treatment, PAI-1 was significantly correlated with AHI (r=0.47, p=0.001) and mean nighttime SpO2 (r=−0.32, p=0.035), but these OSA measures were not significantly related with VWF:Ag, sTF, and D-dimer. AHI was a significant predictor of PAI-1 (R2=0.219, standardized β=0.47, p=0.001), independent of mean nighttime SpO2, body mass index (BMI), and age. A weak time-by-treatment interaction for PAI-1 was observed (p=0.041), even after adjusting for age, BMI, pre-treatment AHI, and mean SpO2 (p=0.046). Post hoc analyses suggested that only CPAP treatment was associated with a decrease in PAI-1 (p=0.039); there were no changes in VWF:Ag, sTF, and D-dimer associated with treatment with placebo–CPAP or with nocturnal oxygen. Apnea severity may be associated with impairment in the fibrinolytic capacity. To the extent that our sample size was limited, the observation that CPAP treatment led to a decrease in PAI-1 in OSA must be regarded as tentative.

Keywords

Cardiovascular disease Fibrinolysis Hemostasis Obstructive sleep apnea Treatment 

References

  1. 1.
    Hung J, Whitford EG, Parsons RW, Hillman DR (1990) Association of sleep apnoea with myocardial infarction in men. Lancet 336:261–264CrossRefPubMedGoogle Scholar
  2. 2.
    Andreas S, Schulz R, Werner GS, Kreuzer H (1996) Prevalence of obstructive sleep apnoea in patients with coronary artery disease. Coron Artery Dis 7:541–545PubMedCrossRefGoogle Scholar
  3. 3.
    Bassetti C, Aldrich MS (1999) Sleep apnea in acute cerebrovascular diseases: final report on 128 patients. Sleep 22:217–223PubMedGoogle Scholar
  4. 4.
    Dyken ME, Somers VK, Yamada T, Ren ZY, Zimmerman MB (1996) Investigating the relationship between stroke and obstructive sleep apnea. Stroke 27:401–407PubMedGoogle Scholar
  5. 5.
    Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, O’Connor GT, Boland LL, Schwartz JE, Samet JM (2001) Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 163:19–25PubMedGoogle Scholar
  6. 6.
    Mooe T, Franklin KA, Holmstrom K, Rabben T, Wiklund U (2001) Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med 164:1910–1913PubMedGoogle Scholar
  7. 7.
    Peker Y, Hedner J, Kraiczi H, Loth S (2000) Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med 162:81–86PubMedGoogle Scholar
  8. 8.
    Saigo M, Hsue PY, Waters DD (2004) Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis 46:524–538CrossRefPubMedGoogle Scholar
  9. 9.
    Folsom AR (2001) Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 86:366–373PubMedGoogle Scholar
  10. 10.
    Shamsuzzaman AS, Gersh BJ, Somers VK (2003) Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 290:1906–1914CrossRefPubMedGoogle Scholar
  11. 11.
    von Känel R, Dimsdale JE (2003) Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 124:1956–1967CrossRefPubMedGoogle Scholar
  12. 12.
    Quan SF, Gersh BJ (2004) Cardiovascular consequences of sleep-disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute. Circulation 109:951–957CrossRefPubMedGoogle Scholar
  13. 13.
    Wessendorf TE, Thilmann AF, Wang YM, Schreiber A, Konietzko N, Teschler H (2000) Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 162:2039–2042PubMedGoogle Scholar
  14. 14.
    Nobili L, Schiavi G, Bozano E, De Carli F, Ferrillo F, Nobili F (2000) Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clin Hemorheol Microcirc 22:21–27PubMedGoogle Scholar
  15. 15.
    Reinhart WH, Oswald J, Walter R, Kuhn M (2002) Blood viscosity and platelet function in patients with obstructive sleep apnea syndrome treated with nasal continuous positive airway pressure. Clin Hemorheol Microcirc 27:201-207PubMedGoogle Scholar
  16. 16.
    Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR (2004) Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 59:777–782CrossRefPubMedGoogle Scholar
  17. 17.
    Geiser T, Buck F, Meyer BJ, Bassetti C, Haeberli A, Gugger M (2002) In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 69:229–234CrossRefPubMedGoogle Scholar
  18. 18.
    Hui DS, Ko FW, Fok JP, Chan MC, Li TS, Tomlinson B, Cheng G (2004) The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 125:1768–1775CrossRefPubMedGoogle Scholar
  19. 19.
    Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K (1995) Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 18:188–194PubMedGoogle Scholar
  20. 20.
    Chin K, Ohi M, Kita H, Noguchi T, Otsuka N, Tsuboi T, Mishima M, Kuno K (1996) Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 153:1972–1976PubMedGoogle Scholar
  21. 21.
    Bokinsky G, Miller M, Ault K, Husband P, Mitchell J (1995) Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest 108:625–630PubMedCrossRefGoogle Scholar
  22. 22.
    Sanner BM, Konermann M, Tepel M, Groetz J, Mummenhoff C, Zidek W (2000) Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 16:648–652CrossRefPubMedGoogle Scholar
  23. 23.
    Bogdanov V, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y (2003) Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9:458–462CrossRefPubMedGoogle Scholar
  24. 24.
    Meyer D, Girma JP (1993) von Willebrand factor: structure and function. Thromb Haemost 70:99–104PubMedGoogle Scholar
  25. 25.
    Lip GY, Lowe GD (1995) Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci 89:205–214PubMedGoogle Scholar
  26. 26.
    Kohler HP, Grant PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792–1801CrossRefPubMedGoogle Scholar
  27. 27.
    Phillips BA, Schmitt FA, Berry DT, Lamb DG, Amin M, Cook YR (1990) Treatment of obstructive sleep apnea. A preliminary report comparing nasal CPAP to nasal oxygen in patients with mild OSA. Chest 98:325–330PubMedCrossRefGoogle Scholar
  28. 28.
    Landsberg R, Friedman M, Ascher-Landsberg J (2001) Treatment of hypoxemia in obstructive sleep apnea. Am J Rhinol 15:311–313PubMedGoogle Scholar
  29. 29.
    Metropolitan Life Foundation (1983) Metropolitan height and weight tables. Stat Bull Metrop Insur Co 64:1Google Scholar
  30. 30.
    Lee KW, Lip GY (2003) Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 163:2368–2392CrossRefPubMedGoogle Scholar
  31. 31.
    Smith PL, Haponik EF, Bleecker ER (1984) The effects of oxygen in patients with sleep apnea. Am Rev Respir Dis 130:958–963PubMedGoogle Scholar
  32. 32.
    Farre R, Hernandez L, Montserrat JM, Rotger M, Ballester E, Navajas D (1999) Sham continuous positive airway pressure for placebo-controlled studies in sleep apnoea. Lancet 353:1154CrossRefPubMedGoogle Scholar
  33. 33.
    Loredo JS, Ancoli-Israel S, Dimsdale JE (1999) Effect of continuous positive airway pressure vs placebo continuous positive airway pressure on sleep quality in obstructive sleep apnea. Chest 116:1545–1549CrossRefPubMedGoogle Scholar
  34. 34.
    Rechtshaffen A, Kales A (1968) A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. NIH, Washington, DCGoogle Scholar
  35. 35.
    Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2:3–9CrossRefPubMedGoogle Scholar
  36. 36.
    Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK (1995) Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 91:284–290PubMedGoogle Scholar
  37. 37.
    Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D (2000) Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96:4212–4215PubMedGoogle Scholar
  38. 38.
    Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE (2002) Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106:491–496CrossRefPubMedGoogle Scholar
  39. 39.
    Milleron O, Pilliere R, Foucher A, de Roquefeuil F, Aegerter P, Jondeau G, Raffestin BG, Dubourg O (2004) Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J 25:728–734CrossRefPubMedGoogle Scholar
  40. 40.
    Chin K, Kita H, Noguchi T, Otsuka N, Tsuboi T, Nakamura T, Shimizu K, Mishima M, Ohi M (1998) Improvement of factor VII clotting activity following long-term NCPAP treatment in obstructive sleep apnoea syndrome. QJM 91:627–633CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Roland von Känel
    • 1
    • 2
  • José S. Loredo
    • 3
  • Sonia Ancoli-Israel
    • 2
    • 4
  • Joel E. Dimsdale
    • 2
  1. 1.Department of General Internal MedicineUniversity Hospital BernBernSwitzerland
  2. 2.Department of PsychiatryUniversity of California San DiegoLa JollaUSA
  3. 3.Department of MedicineUniversity of CaliforniaSan DiegoUSA
  4. 4.Veterans Affairs San Diego Healthcare SystemSan DiegoUSA

Personalised recommendations